摘要
目的:探讨门冬氨酸钾镁在急性心肌梗死治疗中的的疗效及安全性。方法:采用随机、单盲将86例急性心肌梗死患者分为门冬氨酸钾镁治疗组和对照组治疗组在急性心肌梗死的当日,静滴门冬氨酸钾镁100ml,第2～5日静滴剂量每日50ml,第6日改为口服。比较两组治疗后QTcd、心律失常发生的种类、心肌耗氧指数、心力衰竭的发生率和心肌梗死后1月内死亡率。结果:治疗组QTcd、室性心律失常发生率、心肌耗氧指数、心力衰竭的发生率和心肌梗死后1月内死亡率均低于对照组(P<0.05)。结论:在急性心肌梗死中应用门冬氨酸钾镁是有效的、安全的。
Objective：To investigate the curative efect and security of potassium-magnesium aspartate in acute myocardial infarction.Methods：Eighty-six patients were prospectively,randomly assigned in a one-blind fashion to receive intravenous potassium magnesium aspartate（magnesium group,n= 44） or controls（placebo group,n= 42）.We prospectively examined the effect of potassium-magnesium aspartate treatment on the changes of QTcd,the kind of cardiac arrhythmia,oxygen consumption index,the incidence of arrhythmia and heart failure and the mortality in hospital.Results：QTcd,oxygen consumption index,the incidence of ventricular arrhyth,heart failure and the mortality of the therapy group were lower than control group（P0.05）Conclusions：Potassium-magnesium aspartate is a safe and useful.
出处
《现代生物医学进展》
CAS
2010年第8期1491-1493,共3页
Progress in Modern Biomedicine
关键词
门冬氨酸钾镁
急性心肌梗死
心律失常
心力衰竭
死亡率
Potassium magnesium aspartate
Acute myocardial infarction
Cardiac arrhythmias
Heart failure
Mortality
